Ovid Therapeutics OVID Stock
Ovid Therapeutics Price Chart
Ovid Therapeutics OVID Financial and Trading Overview
| Ovid Therapeutics stock price | 2.69 USD |
| Previous Close | 2.63 USD |
| Open | 2.69 USD |
| Bid | 2.68 USD x 100 |
| Ask | 2.69 USD x 100 |
| Day's Range | 2.64 - 2.73 USD |
| 52 Week Range | 1.12 - 3.11 USD |
| Volume | 1.15M USD |
| Avg. Volume | 2.25M USD |
| Market Cap | 525.35M USD |
| Beta (5Y Monthly) | 0.249 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.21 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.8 USD |
OVID Valuation Measures
| Enterprise Value | 409.13M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.948391 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 331.87064 |
| Price/Book (mrq) | 2.3679578 |
| Enterprise Value/Revenue | 258.452 |
| Enterprise Value/EBITDA | -7.057 |
Trading Information
Ovid Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.249 |
| 52-Week Change | 108.73% |
| S&P500 52-Week Change | 15.30% |
| 52 Week High | 3.11 USD |
| 52 Week Low | 1.12 USD |
| 50-Day Moving Average | 2.62 USD |
| 200-Day Moving Average | 2.22 USD |
OVID Share Statistics
| Avg. Volume (3 month) | 2.25M USD |
| Avg. Daily Volume (10-Days) | 1.39M USD |
| Shares Outstanding | 195.3M |
| Float | 163.39M |
| Short Ratio | 13.47 |
| % Held by Insiders | 6.72% |
| % Held by Institutions | 80.34% |
| Shares Short | 20.67M |
| Short % of Float | 12.11% |
| Short % of Shares Outstanding | 10.59% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | June 30, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -2100.68% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -23.45% |
| Return on Equity (ttm) | -25.96% |
Income Statement
| Revenue (ttm) | 1.58M USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | -88.29% |
| Gross Profit (ttm) | 1.58M USD |
| EBITDA | -57974000 USD |
| Net Income Avi to Common (ttm) | -34477000 USD |
| Diluted EPS (ttm) | -0.21 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 117.22M USD |
| Total Cash Per Share (mrq) | 0.6 USD |
| Total Debt (mrq) | 12.72M USD |
| Total Debt/Equity (mrq) | 6.06 USD |
| Current Ratio (mrq) | 12.386 |
| Book Value Per Share (mrq) | 1.136 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -54773000 USD |
| Levered Free Cash Flow (ttm) | -33121250 USD |
Profile of Ovid Therapeutics
| Country | United States |
| State | NY |
| City | New York |
| Address | Hudson Commons |
| ZIP | 10001 |
| Phone | 646 661 7661 |
| Website | https://www.ovidrx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 23 |
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Q&A For Ovid Therapeutics Stock
What is a current OVID stock price?
Ovid Therapeutics OVID stock price today per share is 2.69 USD.
How to purchase Ovid Therapeutics stock?
You can buy OVID shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Ovid Therapeutics?
The stock symbol or ticker of Ovid Therapeutics is OVID.
Which industry does the Ovid Therapeutics company belong to?
The Ovid Therapeutics industry is Biotechnology.
How many shares does Ovid Therapeutics have in circulation?
The max supply of Ovid Therapeutics shares is 195.3M.
What is Ovid Therapeutics Price to Earnings Ratio (PE Ratio)?
Ovid Therapeutics PE Ratio is now.
What was Ovid Therapeutics earnings per share over the trailing 12 months (TTM)?
Ovid Therapeutics EPS is -0.21 USD over the trailing 12 months.
Which sector does the Ovid Therapeutics company belong to?
The Ovid Therapeutics sector is Healthcare.
Ovid Therapeutics OVID included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26333.04 USD — |
+0.96
|
5.66B USD — | 26283.11 USD — | 26431.22 USD — | — - | 5.66B USD — |
|
US Tech Global Select Market Com
NQGS
US
|
12940.54 USD — |
+0.98
|
— — | 12913.4 USD — | 12988.37 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6924.69 USD — |
+0.05
|
— — | 6924.47 USD — | 7006.06 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1293.65 USD — |
+0.08
|
— — | 1293.64 USD — | 1310.12 USD — | — - | — — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
4000.62 USD — |
-1.26
|
— — | 3927.42 USD — | 4148.65 USD — | — - | — — |
- {{ link.label }} {{link}}
